AI-Based Multimodal Integration for Tumor Microenvironment Analysis and Response Prediction in HCC Treated With TACE Plus Immunotherapy and Targeted Therapy (CHANCE2601)

Sponsor
Gao-jun Teng
Study ID
NCT07584317
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Artificial Intelligence — OTHER
    Investigators utilize a AI-based supportive system to predict clinical outcomes for patients with hepatocellular carcinoma who received TACE combined with immunotherapy and targeted therapy

Study Details

This study aims to prospectively validate a retrospective cohort-derived AI-based multimodal model and explore tumor heterogeneity and the immune microenvironment to guide TACE combined with immunotherapy and targeted therapy in HCC.

Key Dates

First listed
May 13, 2026
Start date
May 18, 2026
Status verified
May 2026
Primary completion
May 31, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
1,170 participants (estimated)

Arms

  • Arm: Retrospective cohort
    Patients with hepatocellular carcinoma who received TACE combined with immunotherapy and targeted therapy, as well as other treatment modalities, will be retrospectively included. Multimodal data from this cohort will be used to develop and train the AI-based model.
  • Arm: Prospective cohort
    Patients with hepatocellular carcinoma who receive TACE combined with immunotherapy and targeted therapy will be prospectively enrolled. Multimodal data, including clinical, imaging, and biospecimen-related data when available, will be collected to validate the AI-based multimodal model.

Primary Outcome Measure

Prediction Performance of the AI Model [ Time Frame: From enrollment to approximately 2 years ]

Central Contacts

Find similar trials

Nationwide
Liver cancer trialsOncology trialsGI oncology trialsHepatology trials

Related Studies